Cencora, Inc. reported strong financial results for its fiscal year 2025 second quarter ended March 31, 2025. Revenue increased 10.3% year-over-year to $75.5 billion. Adjusted diluted EPS rose 16.3% to $4.42 in the fiscal second quarter, compared to $3.80 in the prior year.
The U.S. Healthcare Solutions segment continued to drive performance, with revenue increasing 11.4% to $68.3 billion and operating income up 22.8% to $1.0 billion, partly due to the January 2025 acquisition of RCA. The International Healthcare Solutions segment, however, saw operating income decrease 17.3% to $159.3 million.
Cencora updated its fiscal year 2025 adjusted diluted EPS guidance, raising it to a range of $15.70 to $15.95, up from the previous range of $15.30 to $15.60. The company also declared a quarterly cash dividend of $0.55 per common share, payable June 2, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.